influenza

[Cell Reports] Investigators used flow cytometry, T cell receptor sequencing, single-cell transcriptomics, and cytokine analysis to profile virus-specific CD8+ T cells recognizing the ubiquitous pathogens influenza and cytomegalovirus.

[Revelation Biosciences, Inc.] Revelation Biosciences, Inc. announced the site initiation for its Phase IIb viral challenge study to evaluate the efficacy of intranasal REVTx-99 for the preventive treatment of H3N2 influenza in healthy humans.

[Frontiers in Immunology] Upon influenza A virus (IAV) challenge, scientists found that cells escaping viral infection display increased mRNA expression of type-I interferon stimulated genes and decreased expression of ribosomal genes, relative to both infected cells and those never exposed to IAV.

[eLife] The authors characterized cell free DNA released from specific immune cell types in healthy individuals, cross sectionally and longitudinally.

[Revive Therapeutics Ltd.] Revive Therapeutics Ltd. announced that it has filed an application with the US FDA to receive Orphan Drug Designation for Bucillamine for the prevention of ischemia–reperfusion injury during liver transplantation.

[BMC Medicine] Parasitemia was measured using qPCR; immunogenicity was determined using standard assays. Parasites were rescued into culture for in vitro analyses.